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Drug resistanceMedically intractable epilepsy is a clinical condition of concern that arises when a patient with epilepsy suffers
seizures, despite a trial of two or more antiepileptic drugs (AEDs) suitable for the type of epilepsy that are pre-
scribed at maximum tolerated doses, does not achieve control of seizures. This diagnosis could be related to cor-
tical dysplasias. We report the case of a 5-year-old girl with a previous normal neurological development and no
family history of epilepsywho presentedwith focal-type seizures at age 4. She started treatment by taking differ-
ent AEDs for seizure control. She continued having frequent seizures that sometimes progressed to generalized
seizures and status epilepticus. After a focal cortical resection performed in the area where interictal spikes
were detected, the pathology conﬁrmed a type IIb cortical dysplasia as the cause of the epilepsy. This article dis-
cusses cortical dysplasias as a cause of pharmacoresistant epilepsy and its treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Epilepsy is a commonneurological disorderworldwide. Seizure free-
dom is themainstay therapeutic goal of patients with epilepsy since re-
petitive seizures are associated with an increased risk of intellectual
disabilities, mortality, and other comorbidities.2. Case presentation
The patient is a 5-year-old girl from Costa Ricawho came to our hos-
pital, a high complexity hospital in Bogotá, Colombia, South America, in
January 2011, because of medically intractable epilepsy.
The patient’s seizures started at age 4. She was previously a
healthy girl without any remarkable medical history. Her neurologi-
cal development was normal. At the time she started having seizures,
she was attending kindergarten. There was no family history of
epilepsy.
From the beginning, her seizures started with left-sided head and
eye deviation. The seizures lasted a few seconds, and she recovered im-
mediately. At that time, she was seen by a neurologist, and she started
to take antiepileptic drugs (AEDs). Her brain MRI was normal as well
as her physical and neurological exams. Blood tests including amino
acids were normal.nces, Universidad del Rosario,
2970200x3318.
lderon-Ospina).
. This is an open access article underShe continued having frequent seizures; later, they occurred almost
daily. The seizure semiology remained as before with left-sided head
and eye deviation, but followed with left arm extension and splutter
sound. Sometimes, seizures progressed to a bilateral asymmetric tonic
seizure, lasting for 5 to 10 s. According to parents' report, a video-EEG
showed bilateral discharges without ictal localization.
She had had 2 previous episodes of status epilepticus that needed
hospitalization in the intensive care unit (ICU) for several days. By
the time she was seen by us, she was having several seizures each
day. She had three seizures during a visit in the doctor's ofﬁce at
our facilities, and later, she was admitted in the pediatric ICU with
status epilepticus.
Because of the patient’s seizures, shewas not enrolled in school, and
home schoolingwas difﬁcult because of the side effects of AEDs and sei-
zure frequency. The longest seizure-free period experienced by the pa-
tient was 16 days.
Previous AEDs included the following: carbamazepine, phenobarbi-
tal, lamotrigine (it provoked rash), clonazepam, oxcarbazepine, and
topiramate.
At the time we saw her, she was on levetiracetam, gabapentin,
clobazam, and primidone. Her physical exam revealed ataxia because
of the side effects of AEDs. No cognitive deﬁcit was reported by her
parents.
While she was in the pediatric ICU, a midazolam drip was started, as
well as lacosamide 30 mg/kg. At the same time, continuous video-EEG
was performed. It showed interictal right frontal spikes and ictal right
frontal onset-fast activity. Several clinical seizures were recorded with





Fig. 1. Correlation of the images from the patient's neurologic exam. A. Normal brain MRI. B. Brain CT PET scan. Showing right frontal hypoperfusion. C. Video-EEG ictal right frontal fast
activity at seizure onset. D. Haematoxylin and eosin section from the lesion. Showing a balloon cell, conﬁrming FCD type IIB.
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We performed a brain MRI with special images for cortical dysplasia
that was normal. A brain CT PET scan after the patient’s status epilepti-
cuswas resolved that showed right dorsal frontal hypoperfusion(Fig.1).
During the PET scan time acquisition, video-EEGwas continued; no sei-
zureswere recorded (Fig. 1).4. Treatment
The patient’s case was presented in the neurology/pediatric neurol-
ogy–neurosurgery–radiology conference management for epilepsy
surgery.
One week after the patient’s admission, she underwent a focal
cortical resection guided by neuronavigation and intraoperative
electrocorticography with subdural grid. Focal cortical resection
was performed in the area where interictal spikes were detected.
One electrographic seizure was recorded from the same area. The pa-
thology showed a type IIb cortical dysplasia in the right frontal supe-
rior cortex.5. Outcome and follow-up
After surgery, no seizures were reported, and some AEDs were
discontinued; when she was discharged, she was on lacosamide and
primidone (the patient's parents reported some degree of seizure con-
trol with this medication). Six months after the surgery, the patient
was seizure-free. She was only on lacosamide 20 mg/kg. She went
back to school, and is having a normal neurological development.6. Discussion
Epilepsy is a common neurological disorder occurring during
childhood with an approximate incidence of 45 per 1000 cases
per year [1]. It is characterized by recurrent, unprovoked seizures.
The ﬁrst-line therapy for epilepsy consists of antiepileptic drugs
(AEDs). However, other therapeutic options include surgery, vagus
nerve stimulation, and ketogenic diet when AEDs fail to control sei-
zures. Seizures in approximately 20% of the pediatric population do
not respond to the use of AEDs, and these patients are considered
to have medical intractable epilepsy [1].
Pharmacoresistant epilepsy is deﬁned as failure of adequate trials of
two or three tolerated AEDs, which were adequately chosen and pre-
scribed atmaximum tolerated doses, to achieve seizure freedom [2]. Pa-
tients who are not seizure-free are at increased risk of sudden
unexpected death in epilepsy (SUDEP), intellectual disabilities [3],
poor developmental outcome, and other comorbidities such as depres-
sion. Moreover, it is associated with poor quality of life because of the
side effects of medications, associated comorbidities, and failure to
achieve or loss of independence [4].
Focal cortical dysplasia (FCD) is deﬁned as a localized region of mal-
formed cerebral cortex [5]. It is commonly associated with refractory
epilepsy, and seizure semiology depends on the cerebral region that is
involved. Our patient's pathologywas reported as a FCD type IIb accord-
ing to the FCD classiﬁcation consensus of the ILAE [6]. The pathology
showed the presence of abnormal neurons with deposition of Nissl sub-
stance in their cytoplasm (balloon cells) and alteration in the cortical
layers except the I-cortex layer. Focal cortical dysplasia type II is an im-
portant cause of refractory epilepsy and is usually encountered in
extratemporal cortical regions; our patient's cortical dysplasia was in
the frontal lobe, a region that is commonly involved. Seizures usually
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and why they are medically intractable [5].
The clinical, radiologic, and electrophysiologic studies in our patient
showed a correlation of frontal cortical epilepsy foci with fast activity in
the frontal leads in the EEG and hypoperfusion frontal foci on the PET.
Whilewe performed a brainMRIwith special images for cortical dyspla-
sia, it did not show any structural abnormality in the frontal cortex.
However, studies usually reported the presence of structural abnormal-
ities in the brainMRI in patients with FCD type II, such as blurring of the
cortical white-matter junction, focally increased signal in T2-weighted
imaging, and cortical thinning [5] — ﬁndings that were not seen in our
case.
The presented clinical case is the typical history of a patient with re-
fractory epilepsy. This is a diagnosis that has to be considered when a
patient is not seizure-free despite different trials of AEDs [3]. When
we saw this patient, she was on more than three AEDs, and despite
being on those medications, she went into status epilepticus. We con-
sidered other therapeutic approaches to control seizures since there
was a failure of medical treatment. After discussing the case in conjunc-
tion with neurosurgery and other specialties, the patient underwent
surgery for a focal cortical resection. Since it was a partial-type seizure,
and there was a focus of hypoperfusion on the PET scan that was corre-
lated with continuous spikes in the same area during electrocorticogra-
phy, a cortical resection appeared to offer the best chance to control
seizures in this patient.
On the other hand, other therapeutic options thatmay be considered
for pharmacoresistant epilepsy include vagus nerve stimulation and the
ketogenic diet [3].
There are different case reports and cohorts of patients with
pharmacoresistant epilepsy in the literature [7]. They identify risk fac-
tors to recognize patients who are more likely to develop medically in-
tractable epilepsy. Predictors include abnormal exam results, abnormal
imaging, neonatal seizures, early age at seizure onset, and failure of ﬁrst
AED or failure of the ﬁrst AED to improve seizures or failure of the pa-
tient to respond to AEDs during the ﬁrst year of treatment [1].
7. Learning points
• Epilepsy is a common neurological condition in childhood that is
mainly treated with antiepileptic drugs (AEDs). Other therapeuticoptions include surgery, vagus nerve stimulation, and ketogenic diet
when AEDs fail to achieve seizure freedom.
• Medically intractable epilepsy is considered when there is failure of
trials of two or more AEDs which were adequately prescribed to con-
trol seizures.
• Patients who are not seizure-free are at increased risk of complica-
tions such as intellectual disabilities, poor developmental outcome,
and psychiatric diseases.
• Focal cortical dysplasia type II is associated with medical intractable
epilepsy. Its onset is often in infancy, and clinical manifestations de-
pend on the cerebral cortex that is involved. Patients who fulﬁll the
criteria for medically intractable epilepsy should be referred as soon
as feasible to specialized assessment for surgery epilepsy.
• Surgery for epilepsy is currently a therapeutic option formedically in-
tractable epilepsy in certain cases. However, this therapeutic ap-
proach needs an interdisciplinary group that assures an adequate
assessment of the clinical case in order to offer the best therapeutic
option for the patient.
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